Evidence map›Paper›PMID 36165952›Full record

ArticleInflammatory bowel diseases2023

Development and Validation of a Japanese Version of the Inflammatory Bowel Disease Self-efficacy Scale and Cross-culture Study in Japan and the United States.

Makoto Tanaka, Aki Kawakami, Kayoko Sakagami, Tomoko Terai, Jovelle Fernandez, Laurie Keefer, Hiroaki Ito

Abstract read
In one paragraph

Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cross-national comparison of inflammatory bowel disease burden in China, Japan, the United States, and India: An age-period-cohort analysis of GBD 2021.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Makoto TanakaGraduate School of Health Care Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.ORCID 0000-0002-1826-3111
Aki KawakamiGraduate School of Health Care Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Kayoko SakagamiKinshukai Infusion Clinic, Osaka, Japan.
Tomoko TeraiJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Jovelle FernandezJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Laurie KeeferIcahn School of Medicine at Mount Sinai, New York, USA.
Hiroaki ItoKinshukai Infusion Clinic, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelf-efficacy is an important health outcome for patients with inflammatory bowel disease (IBD). We aimed to develop a Japanese version of the IBD-Self-Efficacy Scale (IBD-SES.J) and compare characteristics of self-efficacy of IBD patients with previously reported results from patients in the United States.

methodsWe conducted a questionnaire survey of patients with IBD from a specialized IBD clinic and respondents recruited online. Self-efficacy of patients in Japan and the United States were compared by Student t test and Cohen d coefficient to gauge effect size.

resultsA total of 919 valid responses were obtained: 482 patients from the specialized IBD clinic and 437 patients from the online survey. Significant differences (P < .01) were observed in the following 3 subscales: "managing stress and emotions," "managing symptoms and disease," and "maintaining remission" when comparing remission and active periods; and known-group validity was mostly confirmed. Cronbach's alpha coefficients of each subscale ranged between 0.85 and 0.94. Intraclass correlation coefficients (95% confidence intervals [CIs]) to assess test-retest reliability of each item were between 0.56 (95% CI, 0.47-0.64) and 0.78 (95% CI, 0.73-0.82). Self-efficacy scores for most items in Japanese patients with IBD were lower compared with patients in the United States, with moderate effect size (Cohen d > 0.5), especially in the subscale "managing stress and emotions."

conclusionsThe study demonstrates the reliability and validity of the IBD-SESJ. Self-efficacy scores for most items in Japanese patients were lower than those of patients in the United States. Further investigation is required to understand cross-cultural score differences.

Indexed as

Inflammatory Bowel DiseasesSelf EfficacyCross-Cultural ComparisonEast Asian PeopleHumansJapanQuality of LifeReproducibility of ResultsSurveys and QuestionnairesUnited StatesCrohn’s diseaseinflammatory bowel diseasepsychometric propertiesself-efficacyulcerative colitis

Identifiers

PMID36165952
PMCPMC10393207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.